Dirucotide
Alternative Names: MBP 8298; SF328Latest Information Update: 05 Nov 2023
At a glance
- Originator AutoImmune; University of Alberta
- Developer BioMS Medical Corporation
- Class Peptides
- Mechanism of Action Immunosuppressants; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 06 Jul 2010 BioMS Medical is now called Medwell Capital Corp.
- 02 Sep 2009 BioMS Medical and Eli Lilly terminate their collaboration for dirucotide
- 06 Oct 2008 BioMS receives a sixth positive review from the independent Data Safety Monitoring Board (DSMB) for the ongoing MINDSET-01 trial in relapsing-remitting Multiple sclerosis in Europe